Quarterly report · Q2
9627.TEDINET S100PT4M
Period2022-05-01 → 2022-10-31
Filed2022-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥171.2bn | 2022-05-01 → 2022-10-31 | Cons. | Net sales |
| Revenue | ¥316.2bn | 2021-05-01 → 2022-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥153.0bn | 2021-05-01 → 2021-10-31 | Cons. | Net sales |
| Operating income | ¥6.8bn | 2022-05-01 → 2022-10-31 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2021-05-01 → 2021-10-31 | Cons. | Operating income |
| Ordinary income | ¥7.3bn | 2022-05-01 → 2022-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥16.0bn | 2021-05-01 → 2022-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.1bn | 2021-05-01 → 2021-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.2bn | 2022-05-01 → 2022-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.1bn | 2021-05-01 → 2021-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.8bn | 2022-05-01 → 2022-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.1bn | 2021-05-01 → 2022-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-05-01 → 2021-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.8bn | 2022-05-01 → 2022-10-31 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-05-01 → 2021-10-31 | Cons. | Profit loss |
| Total assets | ¥231.1bn | at 2022-10-31 | Cons. | Assets |
| Total assets | ¥212.5bn | at 2022-04-30 | Cons. | Assets |
| Total assets | ¥210.4bn | at 2021-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥110.3bn | at 2022-10-31 | Cons. | Liabilities |
| Total liabilities | ¥93.5bn | at 2022-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥120.9bn | at 2022-10-31 | Cons. | Net assets |
| Net assets / equity | ¥119.0bn | at 2022-04-30 | Cons. | Net assets |
| Net assets / equity | ¥115.8bn | at 2021-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥46.7bn | at 2022-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥59.7bn | at 2022-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥43.5bn | at 2022-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥59.5bn | at 2022-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥58.4bn | at 2021-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥55.0bn | at 2021-04-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥8.5bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥26.2bn | 2021-05-01 → 2022-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥17.3bn | 2021-05-01 → 2021-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.6bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.9bn | 2021-05-01 → 2022-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.3bn | 2021-05-01 → 2021-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.8bn | 2021-05-01 → 2022-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.6bn | 2021-05-01 → 2021-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥108.3 | 2022-05-01 → 2022-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.77 | 2022-08-01 → 2022-10-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.47 | 2021-05-01 → 2022-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.68 | 2021-05-01 → 2021-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥57.6 | 2021-08-01 → 2021-10-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 52.3% | at 2022-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.0% | at 2022-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2021-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-05-01 → 2022-10-31 | ¥5.8bn |
| Otherother segments | revenue external | 2022-05-01 → 2022-10-31 | ¥5.8bn |
| Otherother segments | revenue intersegment | 2022-05-01 → 2022-10-31 | ¥31m |
| Otherother segments | segment ordinary income | 2022-05-01 → 2022-10-31 | −¥18m |
| Reconciling Itemsreconciling | revenue | 2022-05-01 → 2022-10-31 | −¥31m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-05-01 → 2022-10-31 | −¥31m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-05-01 → 2022-10-31 | −¥3.8bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2022-05-01 → 2022-10-31 | ¥153.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2022-05-01 → 2022-10-31 | ¥153.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥10.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2022-05-01 → 2022-10-31 | ¥12.2bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2022-05-01 → 2022-10-31 | ¥12.2bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥349m |
| —segment total | revenue | 2022-05-01 → 2022-10-31 | ¥171.2bn |
| —segment total | revenue external | 2022-05-01 → 2022-10-31 | ¥171.2bn |
| —segment total | revenue intersegment | 2022-05-01 → 2022-10-31 | ¥31m |
| —segment total | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥11.1bn |
| Otherother segments | revenue | 2021-05-01 → 2021-10-31 | ¥6.3bn |
| Otherother segments | revenue external | 2021-05-01 → 2021-10-31 | ¥6.3bn |
| Otherother segments | revenue intersegment | 2021-05-01 → 2021-10-31 | ¥47m |
| Otherother segments | segment ordinary income | 2021-05-01 → 2021-10-31 | −¥121m |
| Reconciling Itemsreconciling | revenue | 2021-05-01 → 2021-10-31 | −¥47m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-05-01 → 2021-10-31 | −¥47m |
| Reconciling Itemsreconciling | segment ordinary income | 2021-05-01 → 2021-10-31 | −¥3.1bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2021-05-01 → 2021-10-31 | ¥136.9bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2021-05-01 → 2021-10-31 | ¥136.9bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2021-05-01 → 2021-10-31 | ¥10.5bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2021-05-01 → 2021-10-31 | ¥9.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2021-05-01 → 2021-10-31 | ¥9.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2021-05-01 → 2021-10-31 | −¥1.1bn |
| —segment total | revenue | 2021-05-01 → 2021-10-31 | ¥153.0bn |
| —segment total | revenue external | 2021-05-01 → 2021-10-31 | ¥153.0bn |
| —segment total | revenue intersegment | 2021-05-01 → 2021-10-31 | ¥47m |
| —segment total | segment ordinary income | 2021-05-01 → 2021-10-31 | ¥9.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 565
| Item | Context | Value | Unit |
|---|---|---|---|
| Commission fee noi | Prior1YTDDuration | 4000000 | JPY |
| Commission fee noi | CurrentYTDDuration | 10000000 | JPY |
| Real estate rent noi | Prior1YTDDuration | 281000000 | JPY |
| Real estate rent noi | CurrentYTDDuration | 97000000 | JPY |
| Fiduciary obligation fee noi | Prior1YTDDuration | 73000000 | JPY |
| Fiduciary obligation fee noi | CurrentYTDDuration | 106000000 | JPY |
| Subsidy income noi | Prior1YTDDuration | 47000000 | JPY |
| Subsidy income noi | CurrentYTDDuration | 96000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YTDDuration | 2000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYTDDuration | － | JPY |
| Other noi | Prior1YTDDuration | 208000000 | JPY |
| Other noi | CurrentYTDDuration | 320000000 | JPY |
| Non operating income | Prior1YTDDuration | 660000000 | JPY |
| Non operating income | CurrentYTDDuration | 686000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 22000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 27000000 | JPY |
| Loss on transfer of receivables noe | Prior1YTDDuration | 41000000 | JPY |
| Loss on transfer of receivables noe | CurrentYTDDuration | 48000000 | JPY |
| Rent expenses on real estates noe | Prior1YTDDuration | 199000000 | JPY |
| Rent expenses on real estates noe | CurrentYTDDuration | 42000000 | JPY |
| Other noe | Prior1YTDDuration | 46000000 | JPY |
| Other noe | CurrentYTDDuration | 68000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 309000000 | JPY |
| Non operating expenses | CurrentYTDDuration | 187000000 | JPY |
| Ordinary income | Prior1YTDDuration | 6127000000 | JPY |
| Ordinary income | CurrentYTDDuration | 7283000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 26000000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | 2000000 | JPY |
| Gain on transfer of business ei | Prior1YTDDuration | 5000000 | JPY |
| Gain on transfer of business ei | CurrentYTDDuration | 46000000 | JPY |
| Surrender value of insurance ei | Prior1YTDDuration | － | JPY |
| Surrender value of insurance ei | CurrentYTDDuration | 35000000 | JPY |
| Gain on step acquisitions ei | Prior1YTDDuration | 131000000 | JPY |
| Gain on step acquisitions ei | CurrentYTDDuration | － | JPY |
| Other ei | Prior1YTDDuration | 3000000 | JPY |
| Other ei | CurrentYTDDuration | 1000000 | JPY |
| Extraordinary income | Prior1YTDDuration | 167000000 | JPY |
| Extraordinary income | CurrentYTDDuration | 86000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1YTDDuration | 54000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | CurrentYTDDuration | 118000000 | JPY |
| Impairment loss el | Prior1YTDDuration | 6000000 | JPY |
| Impairment loss el | CurrentYTDDuration | 63000000 | JPY |
| Loss on cancellation of leasehold contracts el | Prior1YTDDuration | 118000000 | JPY |
| Loss on cancellation of leasehold contracts el | CurrentYTDDuration | － | JPY |
| Other el | Prior1YTDDuration | 50000000 | JPY |
| Other el | CurrentYTDDuration | 23000000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 230000000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 204000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 6064000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 7165000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |